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Abstract 
Objective: To examine neurocognitive course over time among people with well-treated 
HIV. 
Design: The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) 
study is an ongoing, prospective, longitudinal, multicenter and multilingual study within the 
Swiss HIV Cohort Study (SHCS). Participants undergo neuropsychological assessment at 
baseline and two-yearly follow-up.  
Setting: Seven SHCS centers 
Subjects: Patients aged ≥45 years enrolled in the SHCS with fluency in the local language 
(French, German or Italian) and agreeing to participate in the NAMACO study: 981 
participants at baseline, 720 at two-year follow-up of whom 644 had complete data sets. 
Intervention: Standardized neuropsychological assessment at baseline and two-year follow-
up. 
Main outcome measure: Neurocognitive performance using Frascati criteria and mean z-
scores. 
Results: Four participants (of 644, 0.6%) had plasma HIV-1 RNA >50 copies/mL; median 
CD4 count was 660 cells/μL. According to Frascati criteria, 204 participants (31.7%) had 
neurocognitive impairment (NCI) at baseline. NCI severity in these participants changed little 
over two years and comprehensive models based on Frascati criteria were not feasible. 
Examining mean z-scores, however, we observed neurocognitive stability or improvement 
over two years in five of seven neurocognitive domains assessed. Age ≥65 years (p=0.02) and 
cognitive complaints (p=0.004) were associated with neurocognitive decline, while black race 
(p=0.01) and dolutegravir treatment (p=0.002) were associated with improvement. 
Conclusion: Frascati criteria were less sensitive in measuring NCI change and therefore 
unsuitable for following neurocognitive course in our cohort of people with well-treated HIV. 
Examining neurocognitive course by mean z-score change, we observed stability or 
improvement. 
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Neurocognitive impairment (NCI) has been part of the natural history of HIV since the 
beginning of the pandemic. HIV-associated dementia prevalence has decreased due to the 
availability of safe and effective antiretroviral therapy (ART). However, mild forms of NCI 
remain prevalent even with HIV viral suppression, affecting around 30% of people with HIV 
(PWH).[1,2] Multiple non-HIV-related factors have been associated with NCI, including 
comorbidities, opportunistic infections and depression.[3] It has been argued that high NCI 
prevalence may be related to over-diagnosis of cases using current diagnostic tools.[4,5] 
Against this, longitudinal observational studies have described progression of mild, 
asymptomatic to symptomatic NCI over time.[6,7] 
The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study is a 
longitudinal study created to explore NCI within a well-characterized and well-treated cohort 
of PWH aged ≥45 years old, as part of the Swiss HIV Cohort Study (SHCS).[3] We previously 
presented the results derived from the baseline analyses of the NAMACO study, in which we 
reported NCI prevalence and the main associated factors associated with NCI [3]. In the 
current study, we present the longitudinal analysis of NAMACO study participants, using 
both categorical (NCI according to Frascati criteria)[8] and continuous (annualized changes of 
demographically-adjusted z-scores) NCI definitions. The aim of the study was to examine 
NCI course over time and the main factors associated with neurocognitive performance 
change. 
Methods 
Study design and participants  
The NAMACO study is an ongoing prospective, longitudinal, multicenter and multilingual 
(French, German and Italian) study nested within the SHCS.[3,9] 
SHCS patients aged ≥45 years, followed up at one of seven cantonal hospitals in Switzerland 
(Basel, Bern, Geneva, Lausanne, Lugano, St. Gallen and Zurich) and with sufficient fluency 
in the local language (French, German or Italian) to undergo neuropsychological assessment, 
were invited to participate in the NAMACO study between May 1st 2013 and November 30th 
2016 (baseline). The ethics committees of each cantonal hospital center approved the 
NAMACO study protocol, and all patient participants signed informed consent prior to being 
included.[3] 
A total of 981 participants were recruited at baseline and underwent formal 
neuropsychological assessment. They were then invited to undergo repeat neuropsychological 
assessment at two-year and four-year follow-up visits. The current study examined baseline 
and two-year follow-up data collected between May 2013 and December 2018. 
Procedures 
At baseline and follow-up visits, NAMACO study participants completed a 
neuropsychological test battery covering seven cognitive domains correlated to HIV-
associated NCI based on the International Network for Strategic Initiatives in Global HIV 
trials (INSIGHT) Strategic Timing of AntiRetroviral Treatment (START) study[10] 
(Supplemental Table 1, http://links.lww.com/QAD/C268.). Assessment was conducted by 
trained neuropsychologists. Raw scores derived from testing were converted to a 
demographically-adjusted standard score (z-score). Functional impairment was assessed 
using Lawton’s Instrumental Activities of Daily Living (IADL) and Patient’s Assessment of 
Own Functioning Inventory questionnaire (PAOFI)[11] where impairment was defined as 
difficulties in at least two items out of eleven. Depressive symptoms were assessed using the 
Centre for Epidemiological Studies Depression Scale (CES-D)[12] where CES-D scores of 16-
26 were taken to indicate risk of mild depression and scores ≥27 risk of severe depression. 
Cognitive complaints were assessed using the three European AIDS Clinical Society (EACS) 
screening questions on memory loss, mental slowing and attention difficulties.[13] For each of 
the three EACS screening questions, response options were: never, hardly ever or yes, 
definitely. Participants answering, yes, definitely to at least one question were considered to 
have cognitive complaints as previously described[14].  
We examined NCI categorically using Frascati criteria[8] and continuously using mean z-
scores. Using Frascati criteria, participants were classified as having no NCI, asymptomatic 
neurocognitive impairment (ANI), mild neurocognitive disorder (MND), HIV-associated 
dementia (HAD), and non-HIV-associated NCI. ANI and MND were defined as ≥1 SD below 
mean in ≥2 cognitive domains without (ANI) or with (MND) functional impairment, and 
HAD was defined as ≥2 SD below mean in ≥2 cognitive domains with functional 
impairment. Non-HIV-associated NCI refers to NCI considered to be due to confounding 
conditions such as psychiatric disorders (including depression), substance use, ART toxicity 
and structural damage associated with neurodegenerative disorders, previous opportunistic 
central nervous system (CNS) infection, stroke or trauma. The NAMACO study protocol and 
neuropsychological assessment details have been published elsewhere.[3] 
Participant clinical and demographic characteristics were obtained from the SHCS database 
from six-monthly SHCS visits, taking data from the SHCS visit closest in time to the 
neuropsychological assessment. 
Outcomes 
The primary outcome measures were Frascati category at two-year follow-up, as described 
above, and annualized mean z-score changes. Mean z-scores were calculated for baseline and 
two-year follow-up visits for the different neuropsychological tests across all cognitive 
domains. If neuropsychological tests were used for ≥1 domain they were considered only 
once for the mean z-score calculation. The individual z-score changes were divided by the 
number of years between the baseline and follow-up assessments in order to obtain 
annualized z-score changes. In order to investigate factors associated with Frascati definition 
and z-score changes, we examined demographic and HIV-related characteristics, 
comorbidities, ART changes and CNS penetration effectiveness (CPE) score (based on 
Letendre et al. definitions[15,16] as previously described[17]). 
Statistical analysis 
Analyses were performed through univariable and multivariable linear regression models. 
The following covariables were assessed in our univariable model: age, race/ethnicity, HIV 
acquisition mode, education, employment, depressive symptoms (CES-D), use of 
antidepressants, current intravenous and non-intravenous drug use, smoking, alcohol 
consumption, comorbidities (cardiovascular, metabolic, liver, kidney and bone-related), 
detectable viral load (HIV-1 RNA ≥50 copies/mL), CD4 and CD8 cell counts, CPE score, 
ART changes, hepatitis B or C virus co-infection, and opportunistic infections. We restricted 
our study to participants without missing values for covariables or endpoints (Frascati 
category and mean z-score changes) (figure 1).  
The individual probabilities of dropping out of the study were obtained by multivariable 
logistic regression adjusted for all baseline characteristics. Univariable and multivariable 
linear regression models were subsequently weighted for the inverse probability of dropping 
out of the study. Models were built manually, adding clinical, demographic and other 
baseline characteristics: EACS screening questions, age ≥65 years old, black race, sex, non-
intravenous drug use, depression (CES-D score ≥27 and/or antidepressant treatment), 
CD4/CD8 ratio and HIV-1 viral load. We then added variables with a p-value < 0.2 in 
univariable analyses. The basic model selection (model 1) was based on Akaike and Bayesian 
information criteria. In model 2, we added the CPE score changes and in model 3 we added 
changes in ART. Examining Frascati categories, we observed that NCI changes at two years 
were limited mainly to those between no NCI and ANI. As this could not be adequately 
modelled, we present only descriptive analyses. We used Stata IC 14.2 (StataCorp, College 
Station, TX) for all analyses. 
Role of the funding source 
The study funders had no role in study design, data collection, interpretation or writing of the 
article. The corresponding author had full access to all study data and final responsibility for 
the decision to submit for publication. 
Results 
Of 981 participants recruited at baseline, 720 presented for two-year follow-up of whom 644 
had complete datasets (figure 1). There was no difference in clinical and demographic 
characteristics between these 644 participants and the 337 participants who did not attend or 
had incomplete datasets in terms of median age, sex, race/ethnicity, HIV acquisition mode, 
education, employment, HIV plasma viral load or median CD4 count. Reasons for not 
participating at two-year follow-up are listed in figure 1; 129/337 (48.9%) participants agreed 
to remain in the NAMACO study and attend four-year follow-up. 
At two-year follow-up, participants had a median age of 55 years, with most (70.3%) aged 
45-55 years old, and 16.3% >65 years old. The majority were male (80.8%) and white 
(92.4%) (table 1). Median CD4 count was 660 cells/μL and <1% of participants had 
detectable plasma HIV-1 RNA viremia (table 2). Comparing baseline and follow-up 
characteristics, there were significant differences in age (as the population aged), 
employment (increased retirement due to aging), detectable HIV-1 RNA viremia, detectable 
hepatitis C viremia in co-infected participants (eradication with treatment), and CPE score 
(tables 1 and 2). 
We also found differences in the distribution of Frascati criteria by language-region with 
48%, 72% and 57% having no NCI, and 32%, 20% and 43% having NCI, among French-, 
German-, and Italian-speaking centres, respectively. These differences are partly explained 
by sex, ethnicity, non-injecting drug use, and reported cognitive complaints as measured by 
EACS screening questions. 
Course of NCI and cognitive domains affected 
At two-year follow-up, 204 participants (31.7%) had NCI based on Frascati criteria: 126 
(19.6%) with ANI, seven (1.1%) with MND, three (0.5%) with HAD, and 68 (10.6%) with 
non-HIV-associated NCI. NCI diagnosis changed in 149 participants (23.1%) between 
baseline and follow-up: 86 (57.7%) improved and 63 (42.3%) declined. Most changes 
occurred among participants with ANI who regained normal neurocognitive function (38.3%) 
and participants without NCI who developed ANI (22.1%) (figure 2, panel A and B). Among 
participants with non-HIV-associated NCI, the most common diagnosis was psychiatric 
disorders (70.6%), most frequently depression (93.8%). Of 166 participants with CES-D 
scores of ≥16, 48 (28.9%) were on antidepressants.  
The most affected cognitive domains at follow-up were motor skills (34.5%), attention and 
working memory (27.3%) and speed of information processing (27.0%). We observed a 
significant reduction in participants with sensory and perceptual skills impairment with time 
(table 2). Examining mean z-score change by domain, greatest improvements occurred in 
speed of information processing, language, and executive function (figure 2, panel C). 
Functional impairment, as measured by IADL and PAOFI, was observed in 36 participants 
(5.59%), similar to baseline (p=0.70). 
No patient died from HIV/AIDS related causes. Oncological causes were recorded for six 
patients (Frascati: 2 none, 1 ANI, 1 HAD and 2 other), cardiovascular causes were recorded 
for five patients (2 none, 1 ANI, 2 other), infectious causes were recorded for two patients (1 
none, 1 other), two patients died in accidents (1 none, 1 other), two patients died of suicide (1 
none, 1 ANI). For six patients the cause of death was unknown. There was a significant 
difference in mortality between the different Frascati diagnoses (Fisher’s exact p=0.006, non-
parametric test for trend p=<0.001), but when excluding non-HIV associated NCI, this 
difference disappeared (Fisher’s exact p=0.21, non-parametric test for trend p=0.38). 
Predictors of annualized z-score changes 
Figure 3 shows the results of uni- and multivariable linear regression models for annualized 
z-score changes. Models are weighted with the inverse probability of dropping out, obtained 
from logistic regression with a ROC AUC of 0.7. Univariable analyses showed mean z-score 
decreases (neurocognitive decline) among participants aged >65 years old (p = 0.01) and 
those with cognitive complaints at baseline (p = 0.04). In contrast, black race and ART 
change were independently associated with mean z-score increases. Although the number of 
participants with detectable hepatitis C viremia decreased with time, there was no association 
between hepatitis C treatment and improved neurocognitive performance (data not shown).  
Multivariable analyses were repeated with different sets of covariables starting from our 
initial model (model 1, figure 3, Supplemental table 2, http://links.lww.com/QAD/C268). 
Model 2 added CPE score changes and model 3 added ART changes to a dolutegravir-based 
regimen. We created model 3 because addition of dolutegravir was the most frequent 
treatment change we observed, occurring in 190 patients (29.5%) between baseline and 
follow-up, and because dolutegravir incidentally increases CPE score. After adjusting, the 
factors most strongly associated with annualized mean z-score decreases were cognitive 
complaints at baseline (-0.0416 [95% CI -0.0701 to -0.0131], p=0.004), being aged >65 years 
(-0.0432 [95% CI -0.0799 to -0.0064], p=0.02), and non-intravenous drug use (-0.0338 [95% 
CI -0.0660 to -0.0016], p=0.04) (figure 3, Supplemental table 2, 
http://links.lww.com/QAD/C268). Conversely, starting ART regimens containing 
dolutegravir was associated with mean z-score increases (0.0361 [95% CI 0.0014 to 0.0707], 
p=0.002). An increase in mean z-score was also observed among black race participants 
(0.0698 [95% CI 0.0157 to 0.1239], p=0.01). 
Discussion 
Among PLW aged ≥45 years with well-treated HIV followed up over two years, we have 
observed that the majority of change was between the diagnoses of no NCI, ANI and non-
HIV-associated NCI, with a trend towards improvement. Z-scores changed without changing 
Frascati category, making z-scores a more sensitive means of following NCI course over 
time. Previous cognitive complaints, aging and non-intravenous drug use were associated 
with a decrease in z-scores, while black race and ART changes to dolutegravir were 
associated with an increase. Annualized changes in z-scores across all neurocognitive 
domains, whilst small, were towards improvement. 
The continued use of Frascati criteria[8] in diagnosing HIV-associated NCI is a subject of 
controversy. A limitation of these criteria is the risk of false positive cases, arising from the 
large number of neuropsychological tests performed and the assumption that resulting z-
scores follow a normal distribution which increase the odds of diagnosing ANI by chance.[4,5] 
In the current study, the most prevalent diagnosis at two-year follow-up was ANI (19.6%, 
compared to 24.5% at baseline). Only three participants developed HAD during the same 
period, two previously diagnosed with ANI and one previously diagnosed with MND. Few 
studies have examined the course of ANI. Grant and co-authors reported the course over a 
median of 45 months of 347 patients enrolled in the CHARTER study who had no NCI or 
were diagnosed with ANI at baseline. They observed that patients with ANI had a two- to 
six-fold increased risk of developing symptomatic NCI, based on self-reports (IADL and 
PAOFI) and performance-based tests.[7] However, the CHARTER study population is not 
comparable to ours, as participants had different demographic characteristics and higher 
prevalence of detectable viremia.[6,7] In contrast, Cole and co-authors of the Multicenter 
AIDS Cohort (MAC) study, addressing long-term psychomotor performance prior to the 
arrival of new ART, found that neuropsychological evaluations remained stable after five 
years.[18] In our study among PLW with well-treated HIV, the follow-up period, at two years, 
is relatively short and the z-score changes we observed in individual cognitive domains and 
overall were small. This suggests that follow-up needs to continue over a longer period if 
marked changes in z-scores, or indeed clinically-perceptible differences, are to occur. 
Although z-score changes were associated with clinical, demographic and treatment 
characteristics of our population, our follow-up period was shorter than the CHARTER and 
MAC study follow-up periods.[7,19] If NCI course is slow, we would not notice deterioration 
at the two-year follow-up time point of our study. Analyses of the four-year follow-up data 
will shed light on this. 
The EACS screening questions[13] are part of the standard SHCS clinic visit. Previous studies 
have reported a weak association between these questions and NCI.[20,21] From baseline 
NAMACO study data, we reported low positive and negative predictive values of the EACS 
screening questions for the diagnosis of NCI.[14] In the current study, we looked for a 
longitudinal effect, defining NCI according to both Frascati criteria and mean z-scores to 
avoid possible errors by chance driven by ANI diagnosis. As self-reported tools could be 
indirect markers of depression,[22] and although our models were adjusted for depression, we 
looked for associations excluding participants with CES-D scores >27 and those on anti-
depressants. The association between answering, yes, definitely to at least one EACS 
screening question and NCI remained unchanged whether we examined Frascati categories 
(taking NCI as a dichotomous variable where ANI, MND, HAD and non-HIV-associated 
NCI were grouped as NCI against no NCI) or mean z-scores. In summary, and contrary to 
previous publications, we did find an association between previous cognitive complaints and 
decreased neurocognitive performance at follow-up, even when adjusting for depression. Our 
hypothesis is that the EACS questions could reflect risk of subsequent neurocognitive decline 
rather than immediate neurocognitive performance.  
Unsurprisingly, we noted a negative effect of aging on neurocognitive performance. There is 
no clear evidence for a putative accelerated decline of neurocognitive function in 
PWH.[1,19,23,24] Authors from the MAC study reported that the association between NCI and 
aging in HIV patients is not a linear process, with accelerated or natural decline being a 
consequence of multiple factors but with AIDS being the main driver for premature aging.[25] 
If we consider this non-linearity, and assume different paths according to each patient’s 
characteristics (viral load, CD4 count, opportunistic infections), we could expect a natural 
neurocognitive decline in our well-treated population, as HIV-effects are neutralized. Non-
intravenous drug use was also associated with decreased neurocognitive performance in our 
study. Non-intravenous drug use has been observed to be associated with possible 
confounding factors such as co-medication with agents producing neurocognitive adverse 
effects,[26] depression and anxiety disorders.[27] It is possible that HIV and substance misuse 
work synergistically, affecting different neurological pathways, thus contributing to a double 
burden that leads to further cognitive deterioration.[26]  
We observed that black race and ART changes to dolutegravir were associated with improved 
neurocognitive performance. Regarding black race, although an improvement in z-scores was 
observed, participants were still underperforming, as their mean z-score was negative 
(impaired) at both visits. Although most participants of black race were African, to our 
knowledge there is no evidence for ethnicity/race differences in the psychological tests we 
used which would explain our results. Black participants had lower rates of confounding 
factors (smoking, alcohol and drug consumption) compared to non-black participants, and 
high levels of undetectable viremia. To put our observations into perspective, the observed 
improvement was derived from performance in a single domain, sensory and perceptual 
skills, and this, in a small number of patients, is difficult to interpret. Of note, the 
improvement observed was not associated with antidepressant treatment. Regarding ART 
changes, we observed a decrease in use of the non-nucleoside reverse transcriptase inhibitor 
efavirenz, favoring dolutegravir use, and participants newly-treated with dolutegravir had 
improved neurocognitive performance. Although decreased efavirenz use was driven mainly 
by the fact that dolutegravir was part of new simplified treatment options, stopping efavirenz 
was listed by treating clinicians as being due to neurological or neuropsychological adverse 
effects in 26% of cases. Neuropsychiatric adverse effects associated with efavirenz have been 
widely described.[28,29] However, when analyzing neurocognitive performance in NAMACO 
participants with these complaints, most did not have NCI, and their main complaints were 
sleep deprivation and dizziness. As dolutegravir has the highest possible CPE score (four),[17] 
its increased used possibly explains the trend towards neurocognitive improvement observed 
with higher CPE scores (figure 3). We consider the improved neurocognitive performance in 
participants switched to dolutegravir as being due to an effect of clinical practice, as 
dolutegravir was the most common ART addition in our population (183 participants). 
Hence, as we observed a global trend towards improvement, new participants on dolutegravir 
will also follow this course. To support this argument, participants without ART changes also 
improved neurocognitive performance. We stress that the impact of dolutegravir use needs 
further investigation, especially in the long term, and that our study was not powered to show 
that dolutegravir prevents NCI in our population. 
Our study has limitations. We have a considerable attrition bias due to the high lost to follow-
up rate, which we attempted to account for by weighing our models. Most participants with 
HAD at baseline (four) were lost to follow-up at two years, which limits our understanding of 
factors associated with this group. Moreover, as men who have sex with men and Caucasians 
were over-represented, there is potential recruitment bias. We also found differences in 
neurocognitive performance by centres that can only be partially explained by some 
covariables in our models. These differences were also observed by language region, 
suggesting that the language used for the neuropsychological assessment could play a role in 
these differences. However, as mean z-score change differences between baseline and follow-
up were not large, and as by Frascati criteria we observed a trend to stability, we do not 
consider that language differences affected our study results. One of the strengths is that the 
NAMACO study represents the neurocognitive status of PWH aged ≥45 years old throughout 
Switzerland. As our study recruited not only patients with previous cognitive complaints but 
also those without complaints, we can study NCI incidence as well as NCI course. As 
NAMACO study participants have well-treated HIV, we can examine HIV-associated NCI in 
the ‘best-case’ treatment scenario. Our neuropsychological test battery was performed by 
trained neuropsychologists rather than via computer so that participants with no computer 
skills could still be included. Finally, our assessment was performed in three languages 
(French, German and Italian) to enable the majority of participants to be assessed in their 
native language. 
In conclusion, we found that neurocognitive performance in a well-treated population of 
PWH aged ≥45 years old remains generally stable or improved at two-year follow-up. We did 
not observe that ANI was a portal into more severe NCI but, on the contrary, was associated 
with stable or even improved cognition over time. As a consequence of this stability, we 
consider that Frascati criteria have limitations when analyzing NCI course in populations of 
PWH with low prevalence of non-ANI categories. These findings raise questions about the 
value of stigmatizing PWH with alleged cognitive deficits when they are asymptomatic. 
Analysis of our four-year follow-up data will help address these questions. Finally, the 
factors we observe to be associated with NCI in our population suggest that adequate HIV 
treatment significantly decreases the chances of NCI incidence or progression.  
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Figure 1. Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study 
design IADL, Instrumental Activities of Daily Living; PAOFI, Patients’ Assessment of Own 
Functioning Inventory; CES-D, Centre for Epidemiologic Studies Depression scale; EACS, 
European AIDS Clinical Society. 
 
Figure 2. Panel A: Changes in neurocognitive diagnoses based on Frascati criteria from 
baseline to two-year follow-up. Panel B: Change in neurocognitive diagnosis based on 
Frascati criteria from baseline to two-year follow-up. Panel C: Mean z-score by 
neurocognitive domain assessed at baseline and two-year follow-up; each spoke of the radar 
plot represents a cognitive domain, while spikes represents the magnitude of z-score changes 
per domain. The center of the plot represents the smallest (most negative) average change in 
z-scores we observed between baseline and follow-up (-0.5). ANI, asymptomatic 
neurocognitive impairment; MND, mild neurocognitive disease; HAD, HIV-associated 
dementia. Numbers are expressed in percentages.  
 
Figure 3. Clinical and demographic factors associated with neurocognitive change as 
measured by annualized mean z-scores between baseline and two-year follow-up in 
univariable and multivariable linear regression models. This figure corresponds to the data 
presented in supplemental, table 2, http://links.lww.com/QAD/C268. EACS, European AIDS 
Clinical Society; CES-D, Center for Epidemiological Studies Depression scale; CPE score, 
central nervous system penetration effectiveness score; ART, antiretroviral therapy. 
 
Table 1. Demographic characteristics, HIV acquisition mode and smoking, alcohol and 
drug use data for the 644 patients analyzed at baseline and two-year follow-up. 
 Baseline (N=644) Follow-up 
(N=644) 
p-value 
Median (range) age (years) 53 (49-58) 55 (52-61) <0.001 
Sex    
 Female 124 (19.3%)   
 Male 520 (80.7%)   
Race / Ethnicity    
 White 595 (92.4%)   
 Black 36 (5.6%)   
 Asian 




HIV acquisition mode    
 Heterosexual sex 191 (29.7%)   
 Men who have sex with men 357 (55.4%)   
 Intravenous drug use 75 (11.6%)   
 Other 21 (3.3%)   
Education   1.0 
 Up to obligatory schooling 86 (13.4%) 86 (13.4%)  
 Apprenticeship 316 (49.1%) 316 (49.1%)  
 Secondary education 147 (22.7%) 147 (22.7%)  
 Tertiary education 95 (14.8%) 95 (14.8%)  
Employment   0.01 
 No 169 (26.2%) 173 (26.9%)  
 Yes 405 (62.9%) 366 (56.8%)  
 Retired 70 (10.9%) 105 (16.3%)  
Smoke   0.55 
 Never 224 (34.8%) 221 (34.3%)  
 Former 192 (29.8%) 209 (32.5%)  
 Current 228 (35.4) 214 (33.2%)  
Alcohol consumption   0.24 
 None/mild 537 (83.4%) 552 (85.7%)  
 Moderate/severe 107 (16.6%) 92 (15.3%)  
Current non-intravenous drug use 88 (13.6%) 98 (15.2%) 0.42 
Current intravenous drug use 3 (0.4%) 4 (0.6%) 0.70 
Data are median (IQR), or n (%). P-values obtained by the Pearson chi2 or Fisher exact test 





Table 2. HIV-related, comorbidity and cognitive data for the 644 patients analyzed at 
baseline and two-year follow-up. 
 Baseline (N=644) Follow-up 
(N=644) 
p-value 
HIV-1 RNA >50 copies/mL 20 (3.1%) 4 (0.6%) 0.001 
CD4 nadir (cells per L) 174.5 (74-270) 174.5 (74-270) 1.0 
CD4 count (cells per L) 627.50 (464.5-807.5) 660 (500-870) 0.02 
CD8 count (cells per L) 707.50 (516.5-987) 710 (527-947) 0.76 
CD4/CD8 ratio 0.89 (0.6-1.2) 0.92 (0.6-1.3) 0.05 
Creatinine clearance (CKD-EPI) 87.22 (73.3-98.8) 78.2 (66.9-91.6) <0.001 
CPE score 7 (7-8) 8 (7-9) <0.001 
Treatment regime including 
Dolutegravir 
18 (2.8) 196 (30.4) <0.001 
Comorbidities    
Cardiovascular disease 78 (12.1%) 83 (12.9%) 0.67 
Metabolic disease 44 (6.8%) 46 (7.1%) 0.82 
Liver disease 15 (2.3%) 18 (2.8) 0.59 
Kidney disease 9 (1.4%) 9 (1.4%) 1.0 
Bone disease 99 (15.4%) 107 (16.6%) 0.54 
Hepatitis B 15 (2.3%) 15 (2.3%) 1.0 
Hepatitis C 50 (7.8%) 29 (4.5%) 0.02 
Toxoplasmosis 325 (50.5%) 325 (50.5%) 1.0 
Cytomegalovirus 542 (84.2%) 542 (84.2%) 1.0 
Syphilis (VDRL) 25 (3.9%) 29 (4.5%) 0.78 
Depressive symptoms by CES-D 
scale 
  0.06 
 No symptoms 447 (69.4%) 476 (74.3)  
 Mild depressive symptoms 136 (21.1%) 103 (16.1)  
 Severe depressive symptoms 61 (9.5%) 63 (9.7)  
IADL 45 (6.9%) 36 (5.6%) 0.30 
Neurocognitive domain affected    
Attention and working memory 182 (28.3%) 176 (27.3%) 0.70 
Executive function 133 (20.7%) 96 (14.9%) 0.006 
Language 36 (5.6%) 26 (4.1%) 0.14 
Verbal episodic memory 104 (16.2%) 112 (17.4%) 0.60 
Motor skills 239 (37.1%) 222 (34.5%) 0.32 
Sensory and perceptual skills 22 (3.4%) 6 (0.9%) 0.001 
Speed of information processing 193 (29.9%) 174 (27.0%) 0.24 
Data are median (IQR), or n (%). P-values obtained by the Pearson chi2 or Fisher exact test 
for categorical variables, and by the Wilcoxon rank sum non-parametric test for continuous 
variables. CKD-EPI, chronic kidney disease epidemiological collaboration; CPE score, 
central nervous system penetration effectiveness score; CES-D scale, Center for 
Epidemiological Studies Depression scale; IADL, Instrumental Activities of Daily Living. 
 
 
 
